Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

There are several different approaches to treating sleep apnea that include surgical procedures and oral appliances. Continuous positive airway pressure (CPAP), for example, requi ...

Respiratory Syncytial Virus (RSV) is a major cause of acute respiratory tract infections (ARTIs) and can trigger outbreaks in vulnerable settings such as nursing homes, pediatric wards, and neonatal ...

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who are ...

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

ACIP's first meeting: Inside the unusual, RFK-appointed panel that's deciding on childhood vaccines Merck's shot is the second RSV monoclonal antibody of its kind on the market.

The RSV drug in question, clesrovimab, is recommended for infants younger than 8 months. It was approved in early June, making it the second FDA-approved RSV preventive therapy for young children.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.